Supplementary Data Table 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
收藏数据链接：
官方服务：
资源简介：
MANO method and results. Sheet 1: Primer sequence for the bar code amplification. Sheet 2: Primer sequence for next-generation sequencing analysis. Sheet 3: Raw data for zongertinib (BI 1810631 in table) drug sensitivity assay.
创建时间：
2025-01-13
